Mounjaro maker pauses shipments of weight-loss drug to UK | Pharmaceuticals industry
Weight loss medication Mounjaro producer, the next month before a significant price increase for treatment paused the UK.
US pharmaceutical company Eli Lilly, the United States to allow price deductions in the United States to increase drug producers in Europe to increase the prices of a White House due to the driving force, the UK will increase the list price of the UK up to 170% from September.
The company said it was allocated for pharmacies and providers who ordered drugs from the company to manage their supply and ensure that patients to maintain access.
Eli Lilly said that there are legal protections to prevent inappropriate stocks of drugs by providers. He plans to continue orders on September 1.
The increase in prices may cause the highest dose of one -month drug to increase from £ 122 to £ 330 ($ 165 to $ 445).
Eli Lilly’s two British wholesalers told two wholesalers to stop receiving orders after the demand increased before the price increase entered into force on September 1. Pharmacies, this month since the price announcement of the drug has purchased panic, he said.
People who use Mounjaro were warned against the transition to sellers in the secret economy or collective purchases.
While many of them pay for the drug in the UK, they became available at NHS at the end of June, and Eli Lilly says that the higher price will not affect what is going on in health care.
Mounjaro, also known as the Generic name Tirzepathide, has become a popular alternative to the best -known weight loss medication. Both drugs taken as weekly injections were developed as treatment for type 2 diabetes.
When it was started in England in February 2024, Eli Lilly accepted a list price of a list of other European markets to stop the delays of the drug through NHS.
The company added that the increase in the list price will be more consistently aligned, but NHS will not pay new, higher prices to provide continuous access to obesity and type 2 diabetes patients through health care.
On July 31, Donald Trump sent a letter to 17 of the world’s largest drug producers, including Eli Lilly and Novo Nordisk, and demanded deductions for the Americans within 60 days.
In May, the US President told reporters that a friend in London told him that he had bought a “oil-shot medicine” for $ 88 compared to $ 1,300 in New York.
